Coronavirus Update: How Much Should Remdesivir Cost?

Plus Moderna unveils vaccine manufacturing plans

US cost watchdog ICER has released its cost models for remdesivir, and says it wants to stimulate debate on how it and other COVID-19 therapies should be priced. Plus news from Amgen and ILC Therapeutics.

Barcelona_Queue_Covid19
Barcelona, ​​Spain, 2 May: people enjoying outdoor activities and exercise for the first time after seven weeks of strict lockdown. Italy and France are making similar moves as their death rates continue to decline.

Gilead Sciences Inc.’s remdesivir was given an emergency use approval on Friday 1 May by the US Food and Drug Administration, the first drug to show benefits to patients with COVID-19 and a major step forward in tackling the pandemic.

The approval was based on results from the ACTT adaptive trial released on 29 April which showed that the antiviral...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

More from Scrip

China Sentences Astellas Employee To 3.5 Years In Prison On Spy Charges

 
• By 

An employee of Astellas faces three and a half years in prison after sentencing by a court in China on espionage charges.

Sarepta Restructures, Cuts 500 Jobs As Elevidys-Related Deaths Impact Sales

 
• By 

After a second quarter of declining Elevidys sales following two deaths of DMD patients treated with the gene therapy, Sarepta is cutting costs to fund remaining programs and meet debt requirements.

Hopes Rise For Sickle Cell Gene Therapy Access As 33 States Join CMS Program

 

CMS said that 33 US states plus the District of Columbia and Puerto Rico had joined a program whereby the agency negotiates outcomes-based contracts on their behalf.